Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL Z KOONTZ

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1245410588
CMS profile
911024
Location
MONTEREY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$201.23

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $201.23 6

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $116.89 2
CTI BioPharma Corp. $26.78 1
Janssen Biotech, Inc. $20.08 1
Daiichi Sankyo Inc. $19.64 1
Novocure Inc. $17.84 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL Z KOONTZ

NPI 1245410588 · CMS profile ID 911024

Allopathic & Osteopathic Physicians / Internal Medicine

MONTEREY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245410588?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL Z KOONTZ, NPI 1245410588, CMS profile ID 911024. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245410588?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHAEL Z KOONTZ, NPI 1245410588, CMS profile ID 911024. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245410588?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHAEL Z KOONTZ, NPI 1245410588, CMS profile ID 911024, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1245410588?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $201.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novocure Inc. $17.8409/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021073745 CMS
E.R. Squibb & Sons, L.L.C. $98.3809/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016071225 CMS
Daiichi Sankyo Inc. $19.6408/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006468783 CMS
E.R. Squibb & Sons, L.L.C. $18.5103/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016071147 CMS
CTI BioPharma Corp. $26.7802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039693929 CMS
Janssen Biotech, Inc. $20.0802/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988044183 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $129.98 5
PY2021 $25.96 2
PY2022 $143.20 6
PY2023 $201.23 6
PY2024 $17.85 1
PY2025 $45.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $14,909.95 8
PY2024 Principal investigator $43,471.95 17
PY2023 Recipient $2,028.73 1
PY2023 Principal investigator $390,533.60 22
PY2022 Recipient $152.00 1
PY2022 Principal investigator $356,013.44 26
PY2021 Principal investigator $769,954.46 43
PY2020 Principal investigator $212,543.01 28
PY2019 Recipient $2,721.00 1
PY2019 Principal investigator $48,801.21 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $3,708.56 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 848746707
Principal investigator 1 Merck Sharp & Dohme Corporation $12,981.53 12/31/2021 Non-covered Recipient Entity
Pacific Cancer Care
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 848747215
Principal investigator 1 Merck Sharp & Dohme Corporation $83,809.35 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT-ov65 No dispute reported 06/30/2026 848750663
Principal investigator 1 Merck Sharp & Dohme Corporation $39,096.78 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT-ov65 No dispute reported 06/30/2026 848750665
Principal investigator 1 Merck Sharp & Dohme Corporation $16,342.31 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative HR,HER2- in locally recurrent inoperable or Metastatic Breast Cancer KEYNOTE-B49 No dispute reported 06/30/2026 848750737
Principal investigator 1 Merck Sharp & Dohme Corporation $78,193.56 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative HR,HER2- in locally recurrent inoperable or Metastatic Breast Cancer KEYNOTE-B49 No dispute reported 06/30/2026 848750739
Principal investigator 1 Merck Sharp & Dohme Corporation $35,535.48 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-3475 in Participants with Hematologic Malignancies No dispute reported 06/30/2026 848751541
Principal investigator 1 Merck Sharp & Dohme Corporation $53,292.40 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-3475 in Participants with Hematologic Malignancies No dispute reported 06/30/2026 848751543
Principal investigator 1 Merck Sharp & Dohme Corporation $44,210.25 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754537
Principal investigator 1 Merck Sharp & Dohme Corporation $59,398.08 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754573
Principal investigator 1 Merck Sharp & Dohme Corporation $29,662.64 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed Through or Became Intolerant to Prior Treatment No dispute reported 06/30/2026 848756995
Principal investigator 1 Merck Sharp & Dohme Corporation $112,620.60 12/31/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed Through or Became Intolerant to Prior Treatment No dispute reported 06/30/2026 848756997
Principal investigator 1 Daiichi Sankyo Inc. $2,305.80 12/20/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U301 No dispute reported 06/30/2026 835067745
Principal investigator 1 Genentech, Inc. $11,863.00 12/14/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL No dispute reported 06/30/2026 835984665
Principal investigator 1 Daiichi Sankyo Inc. $4,251.60 12/03/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U301 No dispute reported 06/30/2026 835067541
Principal investigator 1 Merck Sharp & Dohme Corporation $14,875.40 11/26/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-3475 in Participants with Hematologic Malignancies No dispute reported 06/30/2026 848751511
Principal investigator 1 Merck Sharp & Dohme Corporation $51,006.20 11/19/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed Through or Became Intolerant to Prior Treatment No dispute reported 06/30/2026 848756993
Principal investigator 1 Daiichi Sankyo Inc. $3,142.80 10/15/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U301 No dispute reported 06/30/2026 835067263
Principal investigator 1 Daiichi Sankyo Inc. $1,571.40 10/15/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U301 No dispute reported 06/30/2026 835067295
Principal investigator 1 Eli Lilly and Company $55.89 10/14/2021 Non-covered Recipient Entity
MONTEREY BAY ONCOLOGY A MED CORP, DBA PACIFIC CANCER CARE
A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER No dispute reported 06/30/2026 819462829
Principal investigator 1 Eli Lilly and Company $38.20 10/08/2021 Non-covered Recipient Entity
MONTEREY BAY ONCOLOGY A MED CORP, DBA PACIFIC CANCER CARE
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 819463145
Principal investigator 1 Genentech, Inc. $23,464.00 09/01/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL No dispute reported 06/30/2026 835984661
Principal investigator 1 Eli Lilly and Company $43.80 08/26/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819466269
Principal investigator 1 Daiichi Sankyo Inc. $219.60 08/25/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U301 No dispute reported 06/30/2026 835064355
Principal investigator 1 Eli Lilly and Company $166.60 08/06/2021 Non-covered Recipient Entity
MONTEREY BAY ONCOLOGY A MED CORP, DBA PACIFIC CANCER CARE
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 819464295
Principal investigator 1 Eli Lilly and Company $926.05 07/27/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 819466265
Principal investigator 1 Daiichi Sankyo Inc. $3,142.80 07/23/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U301 No dispute reported 06/30/2026 835064173
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 07/16/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY No dispute reported 06/30/2026 816742165
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 07/16/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY No dispute reported 06/30/2026 816742175
Principal investigator 1 Genentech, Inc. $14,700.00 07/09/2021 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL No dispute reported 06/30/2026 836049659
Principal investigator 1 Eli Lilly and Company $1,417.00 06/24/2021 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER No dispute reported 06/30/2026 819465667
Principal investigator 1 Eli Lilly and Company $524.00 06/15/2021 Non-covered Recipient Entity
MONTEREY BAY ONCOLOGY A MED CORP, DBA PACIFIC CANCER CARE
A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER No dispute reported 06/30/2026 819463143
Principal investigator 1 Genentech, Inc. $11,419.00 06/01/2021 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL No dispute reported 06/30/2026 836049611
Principal investigator 1 Daiichi Sankyo Inc. $4,494.60 05/25/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U302 No dispute reported 06/30/2026 835062581
Principal investigator 1 Genentech, Inc. $5,000.00 05/11/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL No dispute reported 06/30/2026 835984653
Principal investigator 1 Daiichi Sankyo Inc. $4,375.80 05/10/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U302 No dispute reported 06/30/2026 835062447
Principal investigator 1 Daiichi Sankyo Inc. $2,093.63 04/28/2021 Non-covered Recipient Entity
Pacific Cancer Care
DS-8201A No dispute reported 06/30/2026 835061323
Principal investigator 1 Daiichi Sankyo Inc. $7,042.50 04/28/2021 Non-covered Recipient Entity
Pacific Cancer Care
DS-8201A No dispute reported 06/30/2026 835061335
Principal investigator 1 Daiichi Sankyo Inc. $2,232.00 04/09/2021 Non-covered Recipient Entity
Monterey Bay Oncology Dba Pacific Cancer Care
DS8201-A-U302 No dispute reported 06/30/2026 835061487
Principal investigator 1 Genentech, Inc. $1,189.00 02/11/2021 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL No dispute reported 06/30/2026 836049411
Principal investigator 1 Daiichi Sankyo Inc. $7,175.25 01/14/2021 Non-covered Recipient Entity
Pacific Cancer Care
DS-8201A No dispute reported 06/30/2026 835054421
Principal investigator 1 Merck Sharp & Dohme Corporation $5,000.00 01/13/2021 Non-covered Recipient Entity
PACIFIC CANCER CARE
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 848747213
Principal investigator 1 Eli Lilly and Company $7,567.00 01/12/2021 Non-covered Recipient Entity
MONTEREY BAY ONCOLOGY A MED CORP, DBA PACIFIC CANCER CARE
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819462827